PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Unit of Medical Oncology, University of Perugia, Perugia, Italy mario.mandala@unipg.it.\', \'Medical Oncology-Melanoma, The Christie Hospital NHS Trust, Manchester, UK.\', \'Division of cancer sciences, The University of Manchester, Manchester, UK.\', \'Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Lombardia, Italy.\', \'Oncology, Fondazione per la Ricerca Ospedale Maggiore, Bergamo, Italy.\', \'Unit of Medical Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy.\', \'Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy.\', \'Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
  • e00169410.1136/jitc-2020-001694
?:doi
?:hasPublicationType
?:journal
  • Journal for immunotherapy of cancer
is ?:pmid of
?:pmid
?:pmid
  • 33593827
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.798
?:rankingScore_hIndex
  • 26
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33593827>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33593827>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all